Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Evans

Vascular Surgery Newark, DE Medical Doctor

NPI 1992818421 CMS profile 903811

1 Centurian Dr Ste 307, Newark, DE 19713

Open in the dashboard

General payments

$3,923

83 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Evans of Newark, DE is reported in the CMS Open Payments database as having received $3,923 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $419 6
2024 General $591 10
2023 General $752 17
2022 General $1,426 28
2021 General $257 6
2020 General $37 2
2019 General $440 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Evans
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Thomas Evans were reported at $419. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Thomas Evans Vascular Surgery median Middle half National median
2019 $440 $796 $226–$2,363 $163
2020 $37 $348 $118–$1,110 $114
2021 $257 $471 $158–$1,421 $132
2022 $1,426 $725 $222–$2,183 $149
2023 $752 $836 $257–$2,440 $160
2024 $591 $909 $252–$2,619 $164
2025 $419 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,052 41 payments
  2. Boston Scientific Corporation $503 14 payments
  3. W. L. Gore & Associates, Inc. $450 7 payments
  4. Inari Medical, Inc. $292 2 payments
  5. Endologix, Inc. $162 2 payments
  6. Philips Electronics North America Corporation $160 2 payments
  7. Janssen Pharmaceuticals, Inc $80 4 payments
  8. Terumo Medical Corporation $51 1 payment
  9. Medtronic Vascular, Inc. $34 2 payments
  10. Silk Road Medical, Inc. $26 1 payment
  11. Other $113 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,923 83 payments
Products named General payments · program years 2019–2025
  1. ENDURANT IIS $1,998 40 payments
  2. FLOWTRIEVER CATHETER, S $292 2 payments
  3. CT THROMBECTOMY SYSTEM KIT $292 2 payments
  4. GORE VIABAHN VBX Balloon Expandable Endo $174 1 payment
  5. GENERAL ULTRASOUND $127 2 payments
  6. General - Vascular Intervention $101 1 payment
  7. GORE TAG Conformable Thoracic Endoprosthesis $94 2 payments
  8. Alto Abdominal Stent Graft System $92 1 payment
  9. GENERAL METALLIC STENTS $87 1 payment
  10. (6536) Phoenix $82 1 payment
  11. Other $1,178 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

128

Median for Vascular Surgery: 122

Drug cost

$24,641

Median for Vascular Surgery: $14,135

Branded share of claims

91.4%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 14 $12,431
Xarelto Rivaroxaban Brand 14 $10,906
Clopidogrel Clopidogrel Bisulfate Brand 77 $1,123
Warfarin Sodium Generic 11 $93
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 12 $88

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 89 billing codes

Paid by Medicare

$144,845

Medicare's payments for the services billed

Medicare patients

784

Average age 74

Services billed

1,392

392 women, 392 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 55%
Arthritis 54%
Ischemic heart disease 49%
Diabetes 48%
Heart failure 36%
Atrial fibrillation 31%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record